In pancreatic cancer, hepatocellular carcinoma, and prostate cancer, SQLE drives tumorigenesis through mechanisms such as activating the PI3K and TGF-β pathways, stimulating cholesterol ester synthesis, and upregulating NADP+ [14, 15, 18]. The gene discussed is TGFB1; the disease is prostate carcinoma.